ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Gilead Sciences, GlaxoSmithKline and Ipsen side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Gilead Sciences×GlaxoSmithKline×Ipsen×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Gilead SciencesGlaxoSmithKlineIpsen
studies on the registry7394,198358
open to participants now3313526
phase 3 studies under way337616
reach primary completion within a year196615
programswith a study of their own in two years3285+17 named only9

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGilead SciencesGlaxoSmithKlineIpsen
Phase 1

Gilead Sciences: 6 of its 32 programs at phase 1

  1. GS-0151phase 1
  2. GS-0415phase 1
  3. GS-1206phase 1
  4. GS-2426phase 1
  5. GS-5319phase 1

and 1 more — sign in to see them all

19%

GlaxoSmithKline: 18 of its 85 programs at phase 1

  1. Pn-MAPS30plusphase 1
  2. GSK4771261phase 1
  3. Antibody-drug Conjugate GSK5533524phase 1
  4. ganfeborolephase 1
  5. GSK4425689Aphase 1

and 13 more — sign in to see them all

21%

Ipsen: 1 of its 9 programs at phase 1

  1. tovorafenibphase 1
11%
Phase 2

Gilead Sciences: 6 of its 32 programs at phase 2

  1. Autologous Anti-CD19/CD20 CAR-T Cells KITE-363phase 2
  2. denikitugphase 2
  3. GS-1179phase 2
  4. GS-4321phase 2
  5. PTM Cilofexor Dose Aphase 2

and 1 more — sign in to see them all

19%

GlaxoSmithKline: 34 of its 85 programs at phase 2

  1. dezecapavirphase 2
  2. nelistotugphase 2
  3. GSK3862995Bphase 2
  4. VH4524184phase 2
  5. nirogacestatphase 2

and 29 more — sign in to see them all

40%
44%
Phase 3

Gilead Sciences: 15 of its 32 programs at phase 3

  1. anitocabtagene autoleucelphase 3
  2. domvanalimabphase 3
  3. teropavimabphase 3
  4. zinlirvimabphase 3
  5. seladelparphase 3

and 10 more — sign in to see them all

47%

GlaxoSmithKline: 23 of its 85 programs at phase 3

  1. belantamab mafodotinphase 3
  2. felcorekibartphase 3
  3. risvutatug rezetecanphase 3
  4. velzatinibphase 3
  5. efimosfermin alfaphase 3

and 18 more — sign in to see them all

27%

Ipsen: 4 of its 9 programs at phase 3

  1. corabotasephase 3
  2. elifibranorphase 3
  3. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3
  4. Palovarotenephase 3
44%
Approved, new studies

Gilead Sciences: 5 of its 32 programs at approved, new studies

  1. sacituzumab govitecanapproved, new study
  2. lenacapavirapproved, new study
  3. tenofovir alafenamideapproved, new study
  4. bictegravirapproved, new study
  5. Emtricitabineapproved, new study
16%

GlaxoSmithKline: 10 of its 85 programs at approved, new studies

  1. dostarlimabapproved, new study
  2. cabotegravirapproved, new study
  3. depemokimabapproved, new study
  4. belimumabapproved, new study
  5. niraparibapproved, new study

and 5 more — sign in to see them all

12%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Gilead Sciences10 readouts · 2 phase 3·

Gilead Sciences, Dec ’26: 2 programs whose next study reaches primary completion

  1. anitocabtagene autoleucelphase 3 · Dec 0 · NCT05396885
  2. sacituzumab govitecanapproved, new study · Dec 0 · NCT04617522
··

Gilead Sciences, Mar ’27: 4 programs whose next study reaches primary completion

  1. domvanalimabphase 3 · Mar 0 · NCT06727565
  2. GS-0151phase 1 · Mar 0 · NCT06902519
  3. lenacapavirapproved, new study · Mar 0 · NCT06749054
  4. Optimized Background Regimen (OBR)phase 3 · Mar 0 · NCT06749054
··

Gilead Sciences, Jun ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. Emtricitabineapproved, new study · Jun 0 · NCT06337032
  2. tenofovir alafenamideapproved, new study · Jun 0 · NCT06337032
·

Gilead Sciences, Aug ’27: 2 programs whose next study reaches primary completion

  1. bictegravirapproved, new study · Aug 0 · NCT07645287
  2. GS-3242phase 3 · Aug 0 · NCT07645287
··
GlaxoSmithKline38 readouts · 8 phase 3

GlaxoSmithKline, Nov ’26: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. dostarlimabapproved, new study · Nov 23 · NCT06567782
  2. Pentetic Acidphase 3 · Nov 23 · NCT07596199
  3. niraparibapproved, new study · Nov 26 · NCT03981796

GlaxoSmithKline, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccinephase 1 · Dec 3 · NCT07464314
  2. momelotinibphase 3 · Dec 11 · NCT03441113
  3. GSK3862995Bphase 2 · Dec 16 · NCT06154837
  4. HFA-152aphase 3 · Dec 28 · NCT07645248
  5. norfluranephase 3 · Dec 28 · NCT07645248

and 1 more — sign in to see them all

GlaxoSmithKline, Jan ’27: 4 programs whose next study reaches primary completion

  1. Adjuvanted RSVPreF3 vaccinephase 2 · Jan 12 · NCT07092865
  2. velzatinibphase 3 · Jan 12 · NCT07862114
  3. SOC INSTI-based ARTphase 1 · Jan 22 · NCT07053384
  4. VH3810109phase 2 · Jan 22 · NCT07053384

GlaxoSmithKline, Feb ’27: 2 programs whose next study reaches primary completion

  1. dezecapavirphase 2 · Feb 18 · NCT07934719
  2. Pn-MAPS30plusphase 1 · Feb 22 · NCT07406334

GlaxoSmithKline, Mar ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. depemokimabapproved, new study · Mar 1 · NCT07671001
  2. CAB ULAphase 3 · Mar 8 · NCT06786520
  3. cabotegravirapproved, new study · Mar 8 · NCT06786520
  4. camlipixantphase 3 · Mar 9 · NCT07519395
  5. ozureprubartphase 2 · Mar 16 · NCT07220811

and 1 more — sign in to see them all

GlaxoSmithKline, Apr ’27: 2 programs whose next study reaches primary completion

  1. felcorekibartphase 3 · Apr 13 · NCT07712393
  2. as01ephase 2 · Apr 23 · NCT07036159

GlaxoSmithKline, May ’27: 3 programs whose next study reaches primary completion

  1. VH4770359phase 1 · May 5 · NCT07525544
  2. gepotidacinphase 3 · May 17 · NCT07645235
  3. GSK4771261phase 1 · May 20 · NCT07600450

GlaxoSmithKline, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Bevacizumabphase 2 · Jun 21 · NCT06796907
  2. belimumabapproved, new study · Jun 29 · NCT06411249
  3. Low dose Strep A Alumphase 1 · Jun 29 · NCT07085702
  4. Low dose Strep A AS37phase 1 · Jun 29 · NCT07085702

GlaxoSmithKline, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mRNA Seasonal Flu vaccinephase 3 · Jul 9 · NCT07851246

GlaxoSmithKline, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. belantamabphase 2 · Aug 5 · NCT07742527
  2. shingrixapproved, new study · Aug 23 · NCT05371080

GlaxoSmithKline, Sep ’27: 1 program whose next study reaches primary completion

  1. mocertatug rezetecanphase 3 · Sep 22 · NCT06431594

GlaxoSmithKline, Oct ’27: 4 programs whose next study reaches primary completion

  1. GSK3772701phase 2 · Oct 8 · NCT07545681
  2. efimosfermin alfaphase 3 · Oct 13 · NCT07358546
  3. Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514phase 2 · Oct 26 · NCT06990880
  4. VH4524184phase 2 · Oct 28 · NCT07202546
Ipsen3 readouts · 1 phase 3·

Ipsen, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. elifibranorphase 3 · Dec 17 · NCT06730061
··

Ipsen, Mar ’27: 1 program whose next study reaches primary completion

  1. corabotasephase 3 · Mar 26 · NCT06937931
······

Ipsen, Oct ’27: 1 program whose next study reaches primary completion

  1. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3 · Oct 15 · NCT04243499
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 24, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Gilead Sciences

New programs 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 6

GlaxoSmithKline

New programs 4

Reached a new phase 0

None

Study stopped 2

  • camlipixantphase 3 · terminated Nov 20“The study has been terminated due to the decision to cease further development of camlipixant in refractory…” · NCT05600777
  • camlipixantphase 3 · terminated Nov 20“The study has been withdrawn terminated due to the decision to cease further development of camlipixant in …” · NCT07650084

Primary completion later 10

Ipsen

New programs 1

  • IPN60350phase 2 · first study · Nov 11 · Neoplasm Metastasis

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 21 in all. A program counts in each condition its studies name most.

ConditionGilead SciencesGlaxoSmithKlineIpsen
Liver Cirrhosis, Biliaryall three · compare here

Gilead Sciences in Liver Cirrhosis, Biliary: 3 programs

  1. seladelparphase 3
  2. cilofexorphase 3
  3. PTM Cilofexor Dose Aphase 2

Their studies: Gilead Sciences’ studies of Liver Cirrhosis, Biliary in search

GlaxoSmithKline in Liver Cirrhosis, Biliary: 1 program

  1. linerixibatphase 3

Their studies: GlaxoSmithKline’s studies of Liver Cirrhosis, Biliary in search

Ipsen in Liver Cirrhosis, Biliary: 1 program

  1. elifibranorphase 3

Their studies: Ipsen’s studies of Liver Cirrhosis, Biliary in search

Neoplasm Metastasisall three · compare here

Gilead Sciences in Neoplasm Metastasis: 1 program

  1. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Neoplasm Metastasis in search

GlaxoSmithKline in Neoplasm Metastasis: 1 program

  1. neladalkibphase 3

Their studies: GlaxoSmithKline’s studies of Neoplasm Metastasis in search

Non-alcoholic Fatty Liver Diseaseall three · compare here

Gilead Sciences in Non-alcoholic Fatty Liver Disease: 2 programs

  1. seladelparphase 3
  2. cilofexorphase 3

Their studies: Gilead Sciences’ studies of Non-alcoholic Fatty Liver Disease in search

GlaxoSmithKline in Non-alcoholic Fatty Liver Disease: 2 programs

  1. efimosfermin alfaphase 3
  2. gatuzosiranphase 2

Their studies: GlaxoSmithKline’s studies of Non-alcoholic Fatty Liver Disease in search

Ipsen in Non-alcoholic Fatty Liver Disease: 1 program

  1. elifibranorphase 3

Their studies: Ipsen’s studies of Non-alcoholic Fatty Liver Disease in search

HIV Infections2 of 3 · compare here

Gilead Sciences in HIV Infections: 5 programs

  1. teropavimabphase 3
  2. zinlirvimabphase 3
  3. lenacapavirapproved, new study
  4. tenofovir alafenamideapproved, new study
  5. Emtricitabineapproved, new study

Their studies: Gilead Sciences’ studies of HIV Infections in search

GlaxoSmithKline in HIV Infections: 14 programs

  1. fostemsavirphase 3
  2. CAB ULAphase 3
  3. dezecapavirphase 2
  4. VH4524184phase 2
  5. VH3810109phase 2

and 9 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of HIV Infections in search

–
Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

Gilead Sciences in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. domvanalimabphase 3
  2. Topotecanphase 3
  3. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Carcinoma, Non-Small-Cell Lung in search

GlaxoSmithKline in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. risvutatug rezetecanphase 3
  2. momelotinibphase 3
  3. neladalkibphase 3
  4. feladilimabphase 3
  5. nelistotugphase 2

and 3 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Carcinoma, Non-Small-Cell Lung in search

–
Neoplasms2 of 3 · compare here

Gilead Sciences in Neoplasms: 2 programs

  1. lurbinectedinphase 3
  2. Topotecanphase 3

Their studies: Gilead Sciences’ studies of Neoplasms in search

–
Breast Neoplasms2 of 3 · compare here

Gilead Sciences in Breast Neoplasms: 4 programs

  1. amrubicinphase 3
  2. lurbinectedinphase 3
  3. trifluridine tipiracil drug combinationphase 2
  4. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Breast Neoplasms in search

GlaxoSmithKline in Breast Neoplasms: 3 programs

  1. nirogacestatphase 2
  2. Bevacizumabphase 2
  3. niraparibapproved, new study

Their studies: GlaxoSmithKline’s studies of Breast Neoplasms in search

–
Ovarian Neoplasms2 of 3 · compare here

Gilead Sciences in Ovarian Neoplasms: 1 program

  1. Topotecanphase 3

Their studies: Gilead Sciences’ studies of Ovarian Neoplasms in search

GlaxoSmithKline in Ovarian Neoplasms: 6 programs

  1. mocertatug rezetecanphase 3
  2. nirogacestatphase 2
  3. Bevacizumabphase 2
  4. ivonescimabphase 2
  5. dostarlimabapproved, new study

and 1 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Ovarian Neoplasms in search

–
Multiple Myeloma2 of 3 · compare here

Gilead Sciences in Multiple Myeloma: 1 program

  1. anitocabtagene autoleucelphase 3

Their studies: Gilead Sciences’ studies of Multiple Myeloma in search

GlaxoSmithKline in Multiple Myeloma: 5 programs

  1. belantamab mafodotinphase 3
  2. feladilimabphase 3
  3. nirogacestatphase 2
  4. belantamabphase 2
  5. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Multiple Myeloma in search

–
Respiratory Syncytial Virus Infections2 of 3 · compare here

Gilead Sciences in Respiratory Syncytial Virus Infections: 1 program

  1. obeldesivirphase 3

Their studies: Gilead Sciences’ studies of Respiratory Syncytial Virus Infections in search

GlaxoSmithKline in Respiratory Syncytial Virus Infections: 5 programs

  1. arexvyphase 3
  2. Adjuvanted RSVPreF3 vaccinephase 2
  3. hMPV_Y low dose vaccinephase 2
  4. RSV/hMPV_V low dose vaccinephase 2
  5. shingrixapproved, new study

Their studies: GlaxoSmithKline’s studies of Respiratory Syncytial Virus Infections in search

–
Small Cell Lung Carcinoma2 of 3 · compare here

Gilead Sciences in Small Cell Lung Carcinoma: 4 programs

  1. amrubicinphase 3
  2. lurbinectedinphase 3
  3. Topotecanphase 3
  4. trifluridine tipiracil drug combinationphase 2

Their studies: Gilead Sciences’ studies of Small Cell Lung Carcinoma in search

GlaxoSmithKline in Small Cell Lung Carcinoma: 2 programs

  1. risvutatug rezetecanphase 3
  2. ivonescimabphase 2

Their studies: GlaxoSmithKline’s studies of Small Cell Lung Carcinoma in search

–
Acquired Immunodeficiency Syndrome2 of 3 · compare here

Gilead Sciences in Acquired Immunodeficiency Syndrome: 2 programs

  1. tenofovir alafenamideapproved, new study
  2. Emtricitabineapproved, new study

Their studies: Gilead Sciences’ studies of Acquired Immunodeficiency Syndrome in search

GlaxoSmithKline in Acquired Immunodeficiency Syndrome: 3 programs

  1. cabotegravirapproved, new study
  2. Dolutegravirapproved, new study
  3. Lamivudineapproved, new study

Their studies: GlaxoSmithKline’s studies of Acquired Immunodeficiency Syndrome in search

–
Colorectal Neoplasms2 of 3 · compare here

Gilead Sciences in Colorectal Neoplasms: 2 programs

  1. denikitugphase 2
  2. trifluridine tipiracil drug combinationphase 2

Their studies: Gilead Sciences’ studies of Colorectal Neoplasms in search

–
Hepatitis B, Chronic2 of 3 · compare here

Gilead Sciences in Hepatitis B, Chronic: 1 program

  1. tenofovir alafenamideapproved, new study

Their studies: Gilead Sciences’ studies of Hepatitis B, Chronic in search

GlaxoSmithKline in Hepatitis B, Chronic: 3 programs

  1. GSK-3965193phase 2
  2. bepirovirsenapproved, new study
  3. Lamivudineapproved, new study

Their studies: GlaxoSmithKline’s studies of Hepatitis B, Chronic in search

–
Cholangitis, Sclerosing2 of 3 · compare here

Gilead Sciences in Cholangitis, Sclerosing: 2 programs

  1. seladelparphase 3
  2. cilofexorphase 3

Their studies: Gilead Sciences’ studies of Cholangitis, Sclerosing in search

–

Ipsen in Cholangitis, Sclerosing: 1 program

  1. elifibranorphase 3

Their studies: Ipsen’s studies of Cholangitis, Sclerosing in search

Endometrial Neoplasms2 of 3 · compare here

Gilead Sciences in Endometrial Neoplasms: 1 program

  1. Topotecanphase 3

Their studies: Gilead Sciences’ studies of Endometrial Neoplasms in search

GlaxoSmithKline in Endometrial Neoplasms: 2 programs

  1. mocertatug rezetecanphase 3
  2. dostarlimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Endometrial Neoplasms in search

–
Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here

Gilead Sciences in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. domvanalimabphase 3

Their studies: Gilead Sciences’ studies of Squamous Cell Carcinoma of Head and Neck in search

GlaxoSmithKline in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. feladilimabphase 3
  2. nelistotugphase 2

Their studies: GlaxoSmithKline’s studies of Squamous Cell Carcinoma of Head and Neck in search

–
Arthritis, Rheumatoid2 of 3 · compare here

Gilead Sciences in Arthritis, Rheumatoid: 1 program

  1. GS-0151phase 1

Their studies: Gilead Sciences’ studies of Arthritis, Rheumatoid in search

GlaxoSmithKline in Arthritis, Rheumatoid: 1 program

  1. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Arthritis, Rheumatoid in search

–
Diabetes Mellitus, Type 22 of 3 · compare here–

GlaxoSmithKline in Diabetes Mellitus, Type 2: 1 program

  1. linerixibatphase 3

Their studies: GlaxoSmithKline’s studies of Diabetes Mellitus, Type 2 in search

Ipsen in Diabetes Mellitus, Type 2: 1 program

  1. elifibranorphase 3

Their studies: Ipsen’s studies of Diabetes Mellitus, Type 2 in search

Kidney Diseases2 of 3 · compare here

Gilead Sciences in Kidney Diseases: 1 program

  1. trifluridine tipiracil drug combinationphase 2

Their studies: Gilead Sciences’ studies of Kidney Diseases in search

GlaxoSmithKline in Kidney Diseases: 1 program

  1. GSK4771261phase 1

Their studies: GlaxoSmithKline’s studies of Kidney Diseases in search

–
Triple Negative Breast Neoplasms2 of 3 · compare here

Gilead Sciences in Triple Negative Breast Neoplasms: 1 program

  1. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Triple Negative Breast Neoplasms in search

GlaxoSmithKline in Triple Negative Breast Neoplasms: 1 program

  1. ivonescimabphase 2

Their studies: GlaxoSmithKline’s studies of Triple Negative Breast Neoplasms in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Gilead Sciences 16 of 32 · GlaxoSmithKline 63 of 85 · Ipsen 4 of 9 programs (31 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (GlaxoSmithKline: 17).